HANDA PHARMACEUTICALS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.5 TWD | +1.82% |
|
+3.72% | -23.98% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -23.98% | 597M | - | ||
| +21.28% | 44.4B | B- | ||
| +24.47% | 23.03B | B+ | ||
| +19.22% | 15.14B | - | ||
| +12.87% | 13.12B | B+ | ||
| +44.67% | 11.85B | B | ||
| -9.92% | 6.99B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +13.07% | 5.52B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6620 Stock
- Ratings Handa Pharmaceuticals, Inc.